[Fulminant liver failure in a patient on carbamazepine and levetiracetam treatment associated with status epilepticus].
A 22-year-old female with a history of developmental delay and seizures successfully treated with carbamazepine and levetiracetam developed fulminant hepatic failure and subsequently died. She had been admitted to the hospital following secondary generalized seizures of 35 min duration. A circulatory shock as well as intoxication was taken into consideration during the clinical course. Autopsy failed to reveal a macroscopically discernible cause of death. Significant findings on microscopic examination included acute tubular necrosis in the kidneys, pre-existing marked accumulation of neutral lipid within the hepatocytes as well as hyperacute liver damage with evidence of almost complete hepatocyte necrosis. Carbamazepine and levetiracetam were simultaneously determined from blood and tissues such as liver, lungs, muscle and kidneys by LC-MS/MS following addition of lamotrigine as an internal standard and liquid-liquid extraction. Validation data are given for levetiracetam. Both carbamazepine and levetiracetam were present in blood at concentrations within or below the therapeutic range, respectively. Moreover, tissue concentrations suggested long-term administration of anticonvulsant drugs, which is in accordance with the medical history. After excessive drug concentrations could be ruled out, the metabolic consequences of a prolonged carbamazepine therapy to cause severe hepatic injury in the present case are discussed. A mechanism of injury to the hepatocytes may be membrane damage by either an increased production of free radicals and/or a decreased free radical scavenging capacity. Following ischemia with reperfusion and during hyperthermia, large amounts of free radicals are formed. Induction of the mixed oxidase activity during longterm administration of carbamazepine may also increase production of free radicals, leaving the hepatic cell more vulnerable to oxidative injury.
Skopp
Gisela
G
Institut für Rechtsmedizin und Verkehrsmedizin.
Schmitt
Horst Peter
HP
Pedal
Ingo
I
D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D001344:Autopsy / Q000331:legislation & jurisprudence; D002220:Carbamazepine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology*; D003616:Dandy-Walker Syndrome / Q000150:complications / Q000473:pathology; D004359:Drug Therapy, Combination; D005260:Female; D005609:Free Radicals / Q000378:metabolism; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D000077287:Levetiracetam; D008099:Liver / Q000187:drug effects / Q000473:pathology; D017114:Liver Failure, Acute / Q000139:chemically induced* / Q000473:pathology; D009336:Necrosis; D010889:Piracetam / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000633:toxicity; D013226:Status Epilepticus / Q000188:drug therapy* / Q000473:pathology; D013375:Substance Withdrawal Syndrome / Q000473:pathology; D014018:Tissue Distribution
D000927:Anticonvulsants; D005609:Free Radicals; D002220:Carbamazepine; D000077287:Levetiracetam; D010889:Piracetam